中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

585 records (took 0.025 seconds)

    Signature for Predicting Clinical Outcome in Human HER2+ Breast Cancer
    121.
    发明申请
    Signature for Predicting Clinical Outcome in Human HER2+ Breast Cancer 有权
    预测人类HER2 +乳腺癌临床结果的签名

    公开(公告)号：US20130259858A1

    公开(公告)日：2013-10-03

    申请号：US13829234

    申请日：2013-03-14

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： Eldad Zacksenhaus ,  Jeff Liu

    IPC: C12Q1/68 ,  G01N33/74

    CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/74

    Abstract: A method of predicting outcome in a subject with for example Her2+ (ERα−) breast cancer comprising: a. determining a HTICs expression signature comprising determining an expression level of 2 or more HTICS biomarkers selected from Aurkb, Ccna2, Scrn1, Npy, Atp7b, Chaf1b, Ccnb1 Cldn8, Nrp1, Ccr2, C1qb, Cd74, Vcam1, Cd180, Itgb2, Cd72, St8sia4 Kif11, Plk1, Chek1, Mphosph6, Coro1a, Ccl5, Cd3e Hcls1, Vav1, Plek, Arhgdib, Il2rg, Sash3, Lck, Il2rb, Cybb, Cd79b, Sell, Ccnd2, Tnfrsf1b, Rftn1, Rac2 and Ly86; and b. calculating a signature score, the signature score comprising a sum of HTICs biomarker expression parameters; wherein a signature score greater than a selected cut-off or control signature score is indicative of a poor outcome (HTICS+) and a signature score less than a selected cut-off is indicative of a good outcome (HTICS−). The methods can be used to prognose outcome and/or select suitable treatment. Arrays and kits for use with the methods are also provided.

    Abstract translation: 一种用例如Her2 +（ERα-））乳腺癌预测受试者的结局的方法，包括：a。 确定HTICs表达特征，其包括确定选自Aurkb，Ccna2，Scrn1，Npy，Atp7b，Chaf1b，Ccnb1 Cldn8，Nrp1，Ccr2，C1qb，Cd74，Vcam1，Cd180，Itgb2，Cd72，St8sia4中的2种或更多种HTICS生物标志物的表达水平 Kif11，Plk1，Chek1，Mhosph6，Coro1a，Ccl5，Cd3e Hcls1，Vav1，Plek，Arhgdib，Il2rg，Sash3，Lck，Il2rb，Cybb，Cd79b，Sell，Ccnd2，Tnfrsf1b，Rftn1，Rac2和Ly86; 和b。 计算签名分数，所述签名评分包括HTICs生物标记表达参数之和; 其中大于所选择的截止或控制签名得分的签名得分表示不良结果（HTICS +），而小于选择的截止值的签名评分表示良好结果（HTICS-）。 该方法可用于预测结果和/或选择合适的治疗。 还提供了与方法一起使用的数组和试剂盒。

    APPARATUS, SYSTEM AND METHOD FOR TRACKING DRUGS DURING A REPACKAGING AND ADMINISTERING PROCESS
    122.
    发明申请
    APPARATUS, SYSTEM AND METHOD FOR TRACKING DRUGS DURING A REPACKAGING AND ADMINISTERING PROCESS 审中-公开
    用于在重新包装和管理过程中跟踪药物的装置，系统和方法

    公开(公告)号：US20130181046A1

    公开(公告)日：2013-07-18

    申请号：US13712826

    申请日：2012-12-12

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： Ludwik Fedorko ,  Joseph Fisher ,  Bryan Drew Miller ,  Bryan Kowalchuk

    IPC: G06Q10/08

    CPC classification number: A61J1/2003 ,  A61J1/14 ,  A61J2205/10 ,  A61J2205/20 ,  A61J2205/30 ,  A61J2205/70 ,  A61M2205/6072 ,  A61M2205/6081 ,  G06F19/3456 ,  G06Q10/00 ,  G06Q10/06 ,  G06Q10/08 ,  G06Q10/0875 ,  G06Q50/22 ,  G16H40/20

    Abstract: A system for tracking drugs during a transfer and administering process is configured to reduce labeling errors that can occur during that process. The system includes a storage container reader configured to read a set of one or more storage-container-associated machine-readable indicia positioned on a container containing a drug. The set of one or more storage-container-associated machine-readable indicia identifies the drug. The system further includes, at the point of care of a patient, an indicia-generating device configured to generate machine readable drug-delivery-container-associated indicia identifying the drug based on the storage-container-associated machine-readable indicia. A drug delivery container reader, also located at the point of care, is configured to read both sets of machine readable indicia to verify that the drug delivery container has been correctly labelled. A method implemented by the system results in the reduction in labeling errors.

    Abstract translation: 在传送和管理过程中跟踪药物的系统被配置为减少在该过程中可能发生的标签错误。 该系统包括存储容器读取器，其被配置为读取位于容纳药物的容器上的一组一个或多个存储容器关联的机器可读标记。 一个或多个存储容器相关联的机器可读标记的集合识别该药物。 该系统还包括在患者护理的点处，标记产生装置被配置为基于与存储容器相关联的机器可读标记产生识别药物的机读药物递送 - 容器相关标记。 也位于护理点的药物递送容器读取器被配置为读取两组机器可读标记以验证药物递送容器已被正确标记。 系统实施的方法导致标签错误的减少。

    COMPOSITIONS AND METHODS FOR CLASSIFYING LUNG CANCER AND PROGNOSING LUNG CANCER SURVIVAL
    123.
    发明申请
    COMPOSITIONS AND METHODS FOR CLASSIFYING LUNG CANCER AND PROGNOSING LUNG CANCER SURVIVAL 审中-公开
    用于分类肺癌和预防肺癌的组合物和方法SURVIVAL

    公开(公告)号：US20130065789A1

    公开(公告)日：2013-03-14

    申请号：US13671912

    申请日：2012-11-08

    Applicant: University Health Network ,  British Columbia Cancer Agency Branch

    Inventor： Ming-Sound Tsao ,  Sarit Aviel-Ronen ,  Wan Lam ,  Bradley Coe ,  Chang-Qi Zhu ,  Igor Jurisica

    IPC: C12Q1/68 ,  C40B40/06

    CPC classification number: C12Q1/6837 ,  C12Q1/686 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158 ,  C40B40/06 ,  G01N33/57423 ,  G01N2800/50 ,  G01N2800/56

    Abstract: The application provides methods of prognosmg, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application.

    Abstract translation: 该应用提供了预防，诊断，筛选和分类肺癌患者为不良生存组或良好生存组的方法。 已经鉴定了许多改变的基因组区域，区分肺腺癌（ADC）的亚型，特别是支气管肺泡癌（BAC）和具有BAC特征（AWBF）的侵袭性ADC的亚型，以及在肺ADC患者中表达改变的基因和生物标志物 到不同的生存结果。 这些基因组区域的扩增和/或缺失和/或生物标志物表达谱可用于将患有ADC的患者分类为具有优异存活结果的BAC组，或具有发生转移性复发风险较高的BAC特征组的侵袭性ADC 生存结果较差。 该应用还包括用于应用方法的套件。

    METHODS AND COMPOSITIONS FOR TREATING ALPHA-SYNUCLEIN-MEDIATED NEURODEGENERATION
    126.
    发明申请
    METHODS AND COMPOSITIONS FOR TREATING ALPHA-SYNUCLEIN-MEDIATED NEURODEGENERATION 有权

    公开(公告)号：US20250134895A1

    公开(公告)日：2025-05-01

    申请号：US18684053

    申请日：2022-08-16

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： Lorraine V. Kalia ,  Suneil K. Kalia

    IPC: A61K31/52 ,  A61K31/4178 ,  A61K31/436 ,  A61K31/438 ,  A61K31/513 ,  A61P25/28

    Abstract: Provided is a method of treating a subject with an α-synucleinopathy neurodegenerative disorder, the method comprising administering one or more therapeutic(s) to the subject, a method of treating a subject with a high risk of developing an α-synucleinopathy neurodegenerative disorder, the method comprising administering one or more therapeutic(s) to the subject, wherein the one or more therapeutic(s) is or comprise rifabutin, one or more nucleoside analog reverse transcriptase inhibitor(s), optionally selected from lamivudine, emtricitabine, tenofovir disoproxil funiarate, tenofovir alafenamide, abacavir, zidovudine, didanosine, and/or stavudine, losartan, or a combination thereof.

    NEUROTECHNOLOGY SYSTEM AND METHOD FOR MONITORING SEIZURE DEVELOPMENT AND ASSESSING ANTI-SEIZURE DRUG RESPONSE
    128.
    发明申请
    NEUROTECHNOLOGY SYSTEM AND METHOD FOR MONITORING SEIZURE DEVELOPMENT AND ASSESSING ANTI-SEIZURE DRUG RESPONSE 有权

    公开(公告)号：US20250107747A1

    公开(公告)日：2025-04-03

    申请号：US18899233

    申请日：2024-09-27

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： Nooshin BAHADOR ,  Liang ZHANG ,  Frances SKINNER ,  Milad LANKARANY

    IPC: A61B5/00 ,  G16H20/10 ,  G16H50/20

    Abstract: According to an aspect, there is provided a computer implemented method and an epilepsy monitoring unit for diagnosis, investigation or treatment of seizures. The method includes identifying ictal-related chirp patterns from recordings of electrophysiological signals by determining onset and offset times of the ictal-related chirp patterns, characterizing the ictal-related chirp patterns, classifying spectro-temporal morphology of the ictal-related chirp patterns. According to an aspect, there is provided a computer implemented method for electrophysiological signals. The method including extracting a neuromarker from neural activities recorded as electrophysiological signals and characterizing ictal-related patterns in the electrophysiological signals during ictal discharge. The neuromarker is for assessment of progression of a seizure or efficacy of anti-seizure pharmacological agents.

    SYSTEMS, METHODS, AND DEVICES FOR THREE-DIMENSIONAL IMAGING, MEASUREMENT, AND DISPLAY OF WOUNDS AND TISSUE SPECIMENS
    129.
    发明申请
    SYSTEMS, METHODS, AND DEVICES FOR THREE-DIMENSIONAL IMAGING, MEASUREMENT, AND DISPLAY OF WOUNDS AND TISSUE SPECIMENS 有权

    公开(公告)号：US20250069224A1

    公开(公告)日：2025-02-27

    申请号：US18943247

    申请日：2024-11-11

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： Ralph S. DaCosta ,  Danielle Dunham

    IPC: G06T7/00 ,  A61B5/00 ,  G06T7/33 ,  G16H30/40

    Abstract: The present disclosure provides methods, systems, and devices for coregistering imaging data to form three-dimensional superimposed images of a biological target such as a wound, a tumor, or a surgical bed. A three-dimensional map can be generated by projecting infrared radiation at a target area, receiving reflected infrared radiation, and measuring depth of the target area. A three-dimensional white light image can be created from a captured two-dimensional white light image and the three-dimensional map. A three-dimensional fluorescence image can be created from a captured two-dimensional fluorescence image and the three-dimensional map. The three-dimensional white light image and the three-dimensional fluorescence image can be aligned using one or more fiducial markers to form a three-dimensional superimposed image. The superimposed image can be used to track wound healing and to excise cancerous tissues, for example, breast tumors. Images can be in the form of videos.

Patent Agency Ranking